Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis

ConclusionsIn RA clinical trials, no association was found between baricitinib treatment and MACE, ATE, or CHF. For DVT/PE, 6 events were reported for baricitinib 4 ‐mg but not placebo; during longer‐term evaluation, IRs were similar between doses, consistent over time, and similar to published rates in RA.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - January 21, 2019 Category: Rheumatology Authors: Peter C. Taylor, Michael E. Weinblatt, Gerd R. Burmester, Terence P. Rooney, Sarah Witt, Chad D. Walls, Maher Issa, Claudia A. Salinas, Chadi Saifan, Xin Zhang, Anabela Cardoso, Miguel A. Gonz ález‐Gay, Tsutomu Takeuchi Tags: Full Length Source Type: research